Stockreport

BRIEF-Morphosys says received FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL [Reuters]

MORPHOSYS AG SP ADR  (MPSYY) 
NASDAQ:AMEX Investor Relations: morphosys.com/media-and-investors
PDF BRIEF-Morphosys says received FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL | Reuters Reuters Staff 1 Min Read Oct 23 (Reuter [Read more]